Twinbeech Capital LP Arvinas, Inc. Transaction History

Twinbeech Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$17.83 - $28.04 $2.93 Million - $4.6 Million	164,112 New	164,112 $3.15 Million
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $2.71 Million - $3.89 Million	74,443 New	74,443 $3.07 Million
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $2.1 Million - $3 Million	80,468 New	80,468 $2.2 Million
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $851,389 - $1.25 Million	-11,631 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $703,093 - $980,028	11,631 New	11,631 $896,000

Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $244,581 - $1.03 Million	-12,114 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$22.99 - $36.34 $278,500 - $440,222	12,114 New	12,114 $286,000

237

65.2M

1.23M

372K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $562M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.